Takip et
Brian Rini
Brian Rini
Vanderbilt University Medical Center
vumc.org üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ...
New England Journal of Medicine 378 (14), 1277-1290, 2018
45322018
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
32252019
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
24782019
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
24212009
Renal cell carcinoma
BI Rini, SC Campbell, B Escudier
The Lancet 373 (9669), 1119-1132, 2009
22872009
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik, TE Hutson, ...
The Lancet 378 (9807), 1931-1939, 2011
22322011
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal …
RJ Motzer, MD Michaelson, BG Redman, GR Hudes, G Wilding, RA Figlin, ...
Journal of Clinical Oncology 24 (1), 16-24, 2006
21732006
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
19632020
Sunitinib in patients with metastatic renal cell carcinoma
RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ...
Jama 295 (21), 2516-2524, 2006
16452006
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
13422015
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial
RJ Motzer, BI Rini, DF McDermott, BG Redman, TM Kuzel, MR Harrison, ...
Journal of clinical oncology 33 (13), 1430-1437, 2015
12212015
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ...
Journal of Clinical Oncology 26 (33), 5422-5428, 2008
12022008
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...
Nature medicine 24 (6), 749-757, 2018
11562018
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
11422013
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...
The lancet oncology 17 (7), 917-927, 2016
11222016
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ...
Journal of clinical oncology 28 (13), 2137-2143, 2010
10342010
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...
The Lancet 393 (10189), 2404-2415, 2019
10032019
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
JS Ko, AH Zea, BI Rini, JL Ireland, P Elson, P Cohen, A Golshayan, ...
Clinical cancer research 15 (6), 2148-2157, 2009
9972009
Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer …
BI Rini, V Weinberg, L Fong, S Conry, RM Hershberg, EJ Small
Cancer: Interdisciplinary International Journal of the American Cancer …, 2006
9132006
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
RJ Motzer, B Escudier, P Tomczak, TE Hutson, MD Michaelson, S Negrier, ...
The Lancet Oncology 14 (6), 552-562, 2013
8942013
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20